

New PCDx Report Format: Front Page



Patient Name
Jane Doe

Final Report Date
1/24/2020

**Non-Small Cell Lung Cancer
(NSCLC)**

Paradigm Cancer Diagnostic (PCDx)

Date of Birth: 00/00/0000	Case/Specimen ID: AA00-00000 A0	Turnaround: 3 business days
PCDx Case#: PCDx-19-000000	Collection Site: Brain	Tumor cells: 40%
Physician: Dr. Smith	Collection Date: 00/00/0000	Specimen size: 225 mm ²
Facility: Some Cancer Treatment Center	Received for testing: 00/00/0000	Requirement met: Optimal

Notification if reflex testing required →

Additional testing to be reported in addendum

Testing with FusionPlex will be performed and these results will be reported out in an addendum.

Key treatments based on current NCCN Guideline recommendations →

6 NCCN indications

Therapeutic Option	Indicating biomarkers	Therapeutic Option	Indicating biomarkers
Afatinib	EGFR L858R	Dacomitinib	EGFR L858R
Erlotinib	EGFR L858R	Gefitinib	EGFR L858R
Osimertinib	EGFR L858R	Ramucirumab + Erlotinib	EGFR L858R

High level of interest markers across all tumor types & clinically relevant cancer specific biomarkers →

High Interest

Pan cancer	Type specific
TMB: Low (4mut/mb)	ALK mutation: Wildtype
MSI: Stable	BRAF mutation: Wildtype
BRCA1: Wildtype	EGFR mutation: L858R
BRCA2: Wildtype	ERBB2 mutation: Wildtype
pending fusions	KRAS mutation: Wildtype
TRKpan: Positive	MET CNV: Not Changed
PD-L1 (22C3) Tumor: Negative	MET mutation: Wildtype
PD-L1 (22C3) TILs: Negative	ALK: Negative
PD-L1 (SP142) Tumor: Negative	ROS1: Negative
PD-L1 (SP142): Negative	

New: PD-L1 SP142 clones →

Additional therapeutic options for genomic/proteomic alterations identified →

5 evidence-based therapy associations

Cetuximab	Everolimus	Gemcitabine
Panitumumab	Vandetanib + Docetaxel	

PCDx Report Information in Follow on Pages

- ↻ IHC results / thresholds
- ↻ Specimen details/ image
- ↻ Salient genomic findings
- ↻ * External results (ER/PR/HER2)
- ↻ All genomic findings
- ↻ All recommended therapy details
- ↻ Therapies with reduced benefit
- ↻ Clinical notes
- ↻ Clinical trials
- ↻ Genes neg for small variants
- ↻ Genes neg for copy number variants
- ↻ References

***New: External or previously tested predictive markers can be incorporated into the report for additional therapeutic options**

3 external results		
Biomarker	Type	Value
ER	IHC	Pos
PR	IHC	Pos
HER2	IHC	Neg

The breast cancer predictive marker (ER, PR, HER2) interpretations in this PCDx report are provided courtesy of an extramural anatomic pathology report and/ or provided by the clinical team completing the Paradigm tumor analysis requisition/request. The predictive marker data is passed through onto this report and did not arise from ER, PR, HER2 tumor assay performed by Paradigm.